Intuitive Surgical, Inc.

NASDAQ Global Select
Back to all articles
Bullish +65

Gilead vs. Intuitive Surgical: Which Healthcare Stock Offers the Better Risk-Adjusted Upside?

Earnings report Financial outlook AI-generated analysis

📈 Intuitive Surgical reported fiscal Q2 revenue growth of 19% year-over-year, reaching $2.89 billion driven by a 15% increase in worldwide da Vinci procedure volumes.

🔧 Instruments and accessories revenue increased 18% to $1.73 billion, validating the company's recurring revenue model based on its expanding installed base of 11,710 systems.

📅 Management expects worldwide da Vinci procedure growth between 13.5% and 15.5% for fiscal 2026, targeting a result near the midpoint of that range.

⚠️ The company anticipates non-GAAP gross margins falling to 68-69% in 2026 due to an estimated one-percentage-point tariff impact on costs.

🏭 Intuitive placed 468 da Vinci systems during the quarter, with 246 units being the newer da Vinci 5 model, contributing to a 12% increase in the global installed base.

💰 Non-GAAP EPS reached $2.80 in fiscal Q2, representing significant growth compared to $2.19 reported a year earlier.

📉 Cell Therapy sales declined 14% to $417 million amid competitive headwinds, though this segment is less central to Intuitive's core robotics business than Gilead's HIV focus.

🤖 The da Vinci installed base continues to compound value, as more systems support additional procedures which in turn drive demand for consumables and services.

📊 Management cautioned that tariffs beyond current assumptions could materially affect 2026 financial results, introducing external cost risks to the growth trajectory.

Bullish Signals
  • Intuitive Surgical achieved a 19% year-over-year revenue increase in fiscal Q2, demonstrating robust top-line growth driven by expanding procedure volumes.
  • The company successfully placed 468 da Vinci systems in the quarter, growing its global installed base to 11,710 units and reinforcing its recurring revenue model.
  • Non-GAAP EPS grew significantly to $2.80 from $2.19 a year earlier, indicating strong profitability alongside revenue expansion.
  • Instruments and accessories revenue rose 18% to $1.73 billion, confirming the compounding value of the installed base as procedures increase.
  • Management raised expectations for procedure growth in fiscal 2026, targeting a range of 13.5% to 15.5% with a specific aim to hit the midpoint.
Risk Factors
  • The company expects non-GAAP gross margins to decline to 68-69% in fiscal 2026 due to an estimated one-percentage-point impact from tariffs.
  • Management explicitly warned that additional tariffs beyond current assumptions could materially affect the company's 2026 financial results.
  • Worldwide da Vinci procedure growth slowed slightly to approximately 15% in fiscal Q2 compared to 17% a year earlier, indicating potential deceleration as the business scales.
Full Analysis
Intuitive Surgical (NASDAQ:ISRG) reported strong fiscal Q2 results with revenue increasing 19% year-over-year to $2.89 billion, driven by a 15% rise in worldwide da Vinci procedure volumes. The company's recurring revenue model proved resilient as instruments and accessories revenue grew 18% to $1.73 billion, reflecting the compounding value of its expanding installed base which reached 11,710 systems. Management provided forward-looking guidance expecting procedure growth between 13.5% and 15.5% for fiscal 2026, with a target to land near the midpoint of that range. However, Intuitive faces margin headwinds from tariffs, anticipating a non-GAAP gross margin decline to 68-69% in 2026 due to an estimated one-percentage-point tariff impact, with warnings that additional tariffs could materially affect results. The article contrasts Intuitive's growth trajectory against Gilead Sciences, noting that while Intuitive relies on sustaining its high-growth engine amidst cost pressures, Gilead faces portfolio concentration risks despite strong HIV franchise performance. Analysts highlight the strategic divergence where Intuitive must maintain mid-teens procedure growth rates as the business scales, whereas Gilead seeks diversification beyond its dominant HIV segment. Intuitive Surgical placed 468 da Vinci systems in the quarter, including 246 units of the newer da Vinci 5 model. The company's non-GAAP EPS reached $2.80 compared to $2.19 a year earlier, demonstrating profitability growth alongside revenue expansion. Investors are weighing the risk-adjusted upside of Intuitive's established growth machine against the potential for continued high-level execution required to sustain its market position.